Results 41 to 50 of about 28,764 (283)

COST-EFFECTIVENESS ANALYSIS OF INSULIN, SULFONYLUREA, AND SULFONYLUREA– METFORMIN IN TYPE 2 DIABETES MELLITUS

open access: yes, 2017
Objective: This study aims to compare the cost-effectiveness of insulin therapy, sulfonylureas, and combination of sulfonylureas-metformin in patients with type 2 diabetes mellitus in Sitanala Hospital, Tangerang.Methods: This study employed a cross ...
Endang Laelasari   +2 more
core   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster   +10 more
wiley   +1 more source

Resistência de plantas daninhas aos herbicidas inibidores da ALS na cultura da soja (Glycine max) Weed resistance to ALS - inhibiting herbicides in soybean (Glycine max) crop

open access: yesPlanta Daninha, 2000
As plantas daninhas Bidens pilosa/Bidens subalternans (picão-preto) e Amaranthus quitensis (caruru) são controladas na cultura da soja por diversos herbicidas, sendo os inibidores da acetolactato sintase (ALS) os mais utilizados pelos sojicultores. O uso
P.A. Monqueiro   +2 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed   +7 more
wiley   +1 more source

Revealing the role of increased SK3 expression in sulfonylurea resistance triggered by prolonged exposure

open access: yesNutrition & Diabetes
Background Sulfonylureas have long been utilized in the management of type-2 diabetes mellitus (T2DM) due to their insulin-secretagogue properties. However, their clinical efficacy is hindered by the risk of severe hypoglycemia and secondary sulfonylurea
Jung Gyu Park   +6 more
doaj   +1 more source

Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus

open access: yes, 2007
Sulfonylurea hypoglycemics are mainly metabolized by the cytochrome P450 2C9 ( CYP2C9) enzyme. The CYP2C9*2 and *3 polymorphisms encode proteins with less enzymatic activity and are correlated with elevated serum levels of sulfonylurea, as demonstrated ...
Stricker, Bruno   +11 more
core   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs [PDF]

open access: yes, 2018
Introduction: Sulfonylurea antidiabetics are insulin secretogogues useful in the treatment of type 2 diabetic patients. The probability of adverse drug interactions is high in patients taking sulfonylureas and other drugs including herbal medicines ...
Naina Mohamed Pakkir Maideen   +3 more
core   +2 more sources

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang   +5 more
wiley   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy